Drugs / JNJ-78306358
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04991740 | Oct 2021 → Feb 2023 | neoplasm | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-78306358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04991740 ↗ |
| Route | Subcutaneous | “once-weekly subcutaneous administration” PMID 39105878 ↗ Aug 2024 |
| Target | HLA-G | “human leukocyte antigen-G (HLA-G)” NCT04991740 ↗ |